Telbivudine for chronic hepatitis B: The GLOBE trial

Future Virology

Volumn 3, Issue 4, 2008, Pages 317-323

  Yuen, Man Fung ^a   Lai, Ching Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

ALT normalization; GLOBE trial; HBeAg loss; HBeAg negative; HBeAg positive; HBeAg seroconversion; HBV DNA levels; Lamivudine; Telbivudine; Viral resistance

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DNA VIRUS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYOPATHY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; VIRUS INHIBITION; VIRUS RESISTANCE; VIRUS VIRULENCE;

HEPATITIS B VIRUS;

EID: 55849121225     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.3.4.317     Document Type: Article

References (18)

1. Lai CL, Chien RN, Leung NW et al.: A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339(2), 61-68 (1998).
2. Lai CL, Lim SG, Brown NA et al.: A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 40(3), 719-726 (2004).
3. Lai CL, Leung N, Teo EK et al.: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129(2), 528-536 (2005).
4. Lai CL, Gane E, Liaw YF et al.: Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357(25), 2576-2588 (2007).
5. Marcellin P, Chang TT, Lim SG et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348(9), 808-816 (2003).
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348(9), 800-807 (2003).
7. Lai CL, Shouval D, Lok AS et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354(10), 1011-1020 (2006).
8. Chang TT, Gish RG, de Man R et al.: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354(10), 1001-1010 (2006).
9. Yuen MF, Yuan HJ, Wong DK et al.: Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54(11), 1610-1614 (2005).
10. Lai CL, Yuen MF: The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann. Intern. Med. 147(1), 58-61 (2007).
11. Hsu YS, Chien RN, Yeh CT et al.: Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35(6), 1522-1527 (2002).
12. Chen CJ, Yang HI, Su J et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1), 65-73 (2006).
13. Yuan HJ, Yuen MF, Wong DKH et al.: The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J. Viral. Hepat. 12(4), 373-379 (2005).
14. Fung J, Yuen MF, Yuen JC et al.: Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. Aliment. Pharmacol. Ther. 26(3), 377-382 (2007).
15. Keeffe EB, Dieterich DT, Han SH et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin. Gastroenterol. Hepatol. 4(8), 936-962 (2006).
16. Lok AS, McMahon BJ: Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 39(3), 857-861 (2004).
17. Lai CL, Gane E, Hsu CW et al.: Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs lamivudine. Hepatology 44(4 Suppl. 1), 222A (2006).
18. Zeuzem S, Buti M, Gane EJ et al.: Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B (the GLOBE study). Hepatology 46(4 Suppl. 1), 681A (2007).